TG Therapeutics, Inc. (MHA)' TG-1101 (Ublituximab) In Combination With Ibrutinib Demonstrates Compelling Clinical Activity And Safety Profile In Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL) And Mantle Cell Lymphoma (MCL)
6/13/2014 8:32:12 AM
NEW YORK, June 13, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced preliminary clinical results from its ongoing Phase 2 study of TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib (IMBRUVICA™), the oral BTK inhibitor from Pharmacyclics/Janssen. Data from the Phase 2 study is being presented during the 19th Annual European Hematology Association (EHA) meeting being held in Milan, Italy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by